Document is current
Any future updates will be listed below
-
Authors
Walaszek, Michał https://orcid.org/0009-0001-6105-1528
Cubała, Wiesław Jerzy https://orcid.org/0000-0001-6343-8454
Kachlik, Zofia https://orcid.org/0009-0000-4482-1191
Pastuszak, Michał https://orcid.org/0000-0002-5132-9426
Pastuszak, Krzysztof https://orcid.org/0000-0002-5562-0114
Kwaśny, Aleksander https://orcid.org/0009-0007-4061-775X
-
Funding
Funding for this research was provided by:
Gdański Uniwersytet Medyczny (01-10025/0008245/01/221/221/0/2025)
Gdański Uniwersytet Medyczny (01-10025/0008245/01/221/221/0/2025)
Gdański Uniwersytet Medyczny (01-10025/0008245/01/221/221/0/2025)
Gdański Uniwersytet Medyczny (01-10025/0008245/01/221/221/0/2025)
Gdański Uniwersytet Medyczny (01-10025/0008245/01/221/221/0/2025)
Gdański Uniwersytet Medyczny (01-10025/0008245/01/221/221/0/2025)
- License Information
-
More Information
Article History
Received: 21 February 2025
Revised: 11 April 2025
Accepted: 16 April 2025
First Online: 30 April 2025
Declarations
:
: Michał Walaszek, Zofia Kachlik, and Krzysztof Pastuszak have no conflict of interest. Wiesław Jerzy Cubała has received within the last three years grants from Acadia, Angelini, Beckley Psytech, GH Research, HMNC Brain Health, IntraCellular Therapies, Janssen, MSD, Neumora, Novartis, Otsuka, and Recognify Life Sciences. He has also received honoraria from Angelini, GH Research, Janssen, and Novartis. He is a member of advisory boards: Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis. Aleksander Kwaśny and Michał Pastuszak have received payments from Beckley Psytech, GH Research, and MSD.
